Scholarlink

<p>The 5th edition of the World Health Organization (WHO) and the International Consensus Classification (ICC 2022) recently recognized a subtype of diffuse large B cell lymphoma (DLBCL), respectively called fluid overload-associated large B-cell lymphoma (FO-LBCL) and human herpes virus 8 (HHV8)/Epstein–Barr (EBV)-negative primary effusion-based lymphoma. However, few reports have provided a molecular profile for this entity. We present two cases, both females, who presented to our hospital with, respectively, massive pleural and pericardial effusion, but with no other significant pathological findings, and for both of whom FO-LBCL was the final diagnosis. Both cases exhibited activated and germinal center phenotypes but had distinct mutational profiles. In this report, we consider the diagnosis, focusing on the main clinicopathological features that differentiate it from primary effusion lymphoma (PEL) and other DLBCL subtypes. We report the results of a next generation sequencing study carried out to provide new evidence about the molecular pathogenic mechanisms of this rare, recently described entity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Large B-cell lymphoma associated with fluid overload: two new case reports with molecular insights

  • 期刊论文

  • 发表日期：

    2025年3月6日

查看全文
  • Lucía Pavía Pascual,
  • Francisco Javier Díaz Crespo,
  • Bruno Bernardo Ardaya López,
  • María de los Ángeles Pérez Saénz,
  • Rebeca Manso Alonso,
  • Socorro María Rodríguez Pinilla,
  • Francisco Javier Díaz de la Pinta

摘要

The 5th edition of the World Health Organization (WHO) and the International Consensus Classification (ICC 2022) recently recognized a subtype of diffuse large B cell lymphoma (DLBCL), respectively called fluid overload-associated large B-cell lymphoma (FO-LBCL) and human herpes virus 8 (HHV8)/Epstein–Barr (EBV)-negative primary effusion-based lymphoma. However, few reports have provided a molecular profile for this entity. We present two cases, both females, who presented to our hospital with, respectively, massive pleural and pericardial effusion, but with no other significant pathological findings, and for both of whom FO-LBCL was the final diagnosis. Both cases exhibited activated and germinal center phenotypes but had distinct mutational profiles. In this report, we consider the diagnosis, focusing on the main clinicopathological features that differentiate it from primary effusion lymphoma (PEL) and other DLBCL subtypes. We report the results of a next generation sequencing study carried out to provide new evidence about the molecular pathogenic mechanisms of this rare, recently described entity.